CorMedix Therapeutics (CRMD) Q3 2026 earnings review
CorMedix pulls its 2027 dialysis target, so it buys hospital drugs
CorMedix Therapeutics, a seller of hospital and dialysis infection drugs, hit its steep Medicare price cut while agreeing to buy another drugmaker's products. Third-quarter revenue dropped by almost half to $54.5 million and operating profit excluding one-offs fell to $3.1 million after the initial reimbursement for its main dialysis drug, DefenCath, expired in July. DefenCath sales beat what the second-half plan pointed to only because of a $5 million accounting credit from past rebate reserves. Chief executive Joseph Todisco held the full-year sales outlook steady, leaving fourth-quarter revenue down about 60% from a year ago by our math.
| DefenCath sales (excluding $5M reserve credit) | $12.2M −86% from a year ago by our math ($17.2M reported) |
|---|---|
| Consolidated revenue | $54.5M −48% from a year ago |
| Operating profit, excluding one-offs (Adjusted EBITDA) | $3.1M $71.9M a year ago |
| 2027 DefenCath revenue outlook | Suspended prior target: $100–140M |
⚖️ Verdict: 🔴 Bearish
The story got worse because CorMedix pulled its 2027 DefenCath revenue outlook of $100 million to $140 million after changes to federal Medicare rules, removing the anchor for a rebound next year. To reduce its reliance on dialysis pricing, the company agreed to buy four hospital drugs from Heron Therapeutics that Todisco expects will bring in $125 million to $150 million next year. One positive: the Food and Drug Administration gave its Rezzayo antifungal expansion a fast-track review for early 2027, and collecting spring bills lifted cash to $355 million.
The question now is whether DefenCath can recover in 2027 or stays near its current low run rate while acquired hospital drugs carry the business. Either new customer contracts and private Medicare Advantage plans restore DefenCath pricing, or the quarterly federal payment rules keep dialysis revenue depressed. The reissued 2027 DefenCath outlook in early 2027 will settle it.
🐂 Bull Case
FDA Gave Rezzayo a Fast-Track Review
Rezzayo is an antifungal hospital drug that CorMedix acquired with Melinta. Together with development partner Mundipharma, the drugmaker wants approval to use Rezzayo to prevent fungal infections in bone-marrow transplant patients, which would open a larger market.
In October, the US Food and Drug Administration accepted the application and granted Priority Review, setting a decision deadline in the first quarter of 2027. Chief executive Joseph Todisco said, "If approved, we plan to commence promotional efforts in the second half of 2027." That schedule keeps the launch on track, though it leaves a gap of several months between approval and active selling, and the release still does not disclose how CorMedix splits profit with Mundipharma.
What to watch: the FDA decision in the first quarter of 2027 and any detail on partner profit-sharing. An approval Covering all three fungal types in the trial would give the hospital sales team a major product for late 2027.
Receivables Collection Lifted Cash to $355 Million
Cash generation has been a central positive for CorMedix, while critics warned that delayed customer rebate bills were inflating cash flow and would lock up $59 million in restricted cash. This quarter, unrestricted cash rose by $98.5 million from June to $355.2 million.
By our math, third-quarter operating cash flow reached $89.7 million even though operating profit excluding one-offs was only $3.1 million. That happened because the company collected bills from the high-priced second quarter, reducing trade receivables by $84.6 million to $76.7 million. CorMedix also noted that nine-month cash flow benefited from "working capital movements, including the timing of certain contractual rebate payments", while restricted cash on the balance sheet was only $1.0 million by our math.
What to watch: the rebate liability table and restricted cash footnote in the third-quarter filing. They will show how much of the $355.2 million cash pile is owed back to dialysis clinics for past rebates.
🐻 Bear Case
CorMedix Pulled Its 2027 DefenCath Target
DefenCath is an antimicrobial liquid that prevents bloodstream infections in dialysis patients' catheters. On July 1, its generous initial Medicare reimbursement expired and switched to a much smaller post-launch add-on payment. The recovery story rested on a federal formula that CorMedix estimated would raise the payment three to five times in 2027, supporting its earlier 2027 DefenCath sales target of $100 million to $140 million.
Following recent rule changes from the federal Medicare agency, the drugmaker decided to "suspend any previously issued 2027 DefenCath revenue guidance and defer future guidance until early 2027". Management cited a new quarterly calculation method in the federal rules and said it needs time for "better visibility into 2027 utilization and pricing for customers and any potential upside from Medicare Advantage contracting". Pulling the target removes the main anchor for a 2027 rebound in dialysis revenue.
What to watch: the reissued 2027 DefenCath sales outlook in early 2027. A target well below the old $100 million floor would mean the federal rule change permanently reduced DefenCath's pricing power.
A Rebate Credit Cushioned the DefenCath Drop
CorMedix highlighted steady third-quarter execution after the July 1 Medicare price cut, noting that DefenCath brought in $17.2 million from "largely maintaining utilization of DefenCath by large outpatient dialysis customers in the post-TDAPA period, which impacted price". On the surface, $17.2 million beat the $6 million to $16 million quarterly average implied by the company's second-half outlook.
- Reported DefenCath sales: $17.2 million, down 81% from $88.8 million a year ago
- Underlying DefenCath sales: $12.2 million by our math, down 86% after removing a $5.0 million accounting credit
- Gross margin: 55.0%, down 34.2 percentage points from a year ago
- Production cost and intangible write-offs: up 18.8 points and 15.4 points of revenue, respectively
The beat against the implied plan came from a $5.0 million "favorable change in estimate related to certain sales allowances" — an adjustment to past rebate reserves that CorMedix itself strips out of Adjusted EBITDA. Without that credit, underlying DefenCath sales fell from $66.1 million in the second quarter to $12.2 million, which pulled gross margin down and pushed GAAP operating income to a $6.6 million loss.
What to watch: fourth-quarter DefenCath sales without reserve adjustments, plus patient counts at the fifth major dialysis chain pilot. If underlying quarterly sales stay near $12 million, the new pilot is not offsetting the price cut.
Risks this quarter didn't answer
Five standing concerns from prior filings received no new numbers in the third-quarter earnings release and await the full quarterly report.
- Fifth dialysis chain pilot: no clinic or patient counts after pilot orders began in the third quarter; the conference call or filing may detail 2027 expansion.
- Customer concentration: three buyers accounted for 72% of second-quarter sales; the filing's concentration footnote will show the post-July mix.
- Hospital drug patent and write-down risks: no update on the Minocin generic challenge or potential Kimyrsa and Orbactiv asset write-downs; the legal and accounting footnotes will update both.
- Phase 3 nutrition study (TPN): completion remains set for 2028 with no enrollment numbers in the release.
- Shareholder lawsuits: fact discovery ran through September; the legal contingencies footnote will show any settlement or cost changes.
👓 Other Themes
Heron Deal Doubles the Hospital Drug Business
On November 9, CorMedix agreed to buy almost all the assets of Heron Therapeutics, expected to close in the first quarter of 2027. Todisco said the deal "adds four commercial products used in institutional settings of care and is expected to be immediately accretive to earnings and free cash flow upon closing". He expects $125 million to $150 million of 2027 sales, doubling non-DefenCath product revenue, funded with cash and $75 million from a new $150 million loan.
💲 Other KPIs
Revenue outside DefenCath rose from $35.8 million in the second quarter to $37.3 million. Net product sales from the Melinta hospital drugs grew 11.3% from last quarter to $31.4 million by our math, joined by $3.3 million of grant income and $2.6 million of contract revenue. However, total portfolio revenue remains 11.2% below last year's $42.0 million full-quarter pro forma level.
Inventories — raw materials and finished drugs waiting to be sold — climbed 11.8% from June and 45.2% from $29.7 million at the end of 2025. Stockpiles have grown in all three quarters this year even as total product sales dropped, tying up $13.4 million of working capital over the first nine months.
CorMedix swung from a $26.0 million profit in the second quarter and a $108.6 million tax-boosted profit a year ago to a $14.7 million net loss, or $(0.19) per share. Beyond the DefenCath price drop, results were hit by an $11.5 million non-cash charge from increasing the estimated future milestone payments owed for the Melinta acquisition.
🔮 Guidance
Unchanged. The full-year target still calls for 7.5% growth at the middle of the range. With $283.9 million already booked in the first nine months, the plan leaves $51.1 million for the fourth quarter by our math, down 60.3% from $128.6 million a year ago as the lower post-July DefenCath price continues.
Raised. The drugmaker lifted the bottom of the range by $5 million, moving the middle up $2.5 million to $135 million. It is the third raise this year, and each is smaller than the last: +$12.5M, +$7.5M, +$2.5M. Because nine-month Adjusted EBITDA is already $131.9 million, the middle of the range leaves $3.1 million for the fourth quarter by our math, matching the third quarter.
Cut. Management lowered its target for cash operating costs — which exclude stock compensation and one-off deal fees — by $7.5 million at the middle of the range. It is the second cost reduction this year after a $2.5 million trim last quarter, and it accounts for the higher full-year Adjusted EBITDA floor despite lower DefenCath revenue.
Withdrawn. CorMedix suspended its previously issued 2027 DefenCath revenue outlook and deferred a replacement until early 2027. The prior $100 million to $140 million target assumed the 2027 Medicare add-on payment would jump three to five times above second-half 2026 levels, an assumption now clouded by a new quarterly federal reimbursement formula.
❓ Key Questions
How does the new Medicare formula change 2027 DefenCath pricing?
CorMedix previously estimated its 2027 Medicare add-on payment would be three to five times the second-half 2026 rate. Management suspended the $100–140 million 2027 revenue target without saying whether the new quarterly federal formula lowers the total annual payment or just makes customer contracting harder.
Where did the $59 million rebate letter of credit go?
Last quarter's filing disclosed a deal to delay customer rebate payments backed by a $59 million restricted-cash letter of credit in the third quarter. Yet September restricted cash was only $1.0 million by our math. Did CorMedix pay the rebates in cash or cancel the deferral?
What are Heron's standalone profit margins and full purchase cost?
Chief executive Joseph Todisco expects the Heron assets to add $125–150 million in 2027 sales and boost earnings right away. The earnings release did not state the total purchase price, equity issuance, or how much profit those four hospital drugs currently generate.
How are Rezzayo prophylaxis profits split with partner Mundipharma?
With an FDA decision set for the first quarter of 2027 and marketing starting in the second half, CorMedix still has not disclosed its royalty or milestone obligations to development partner Mundipharma, nor the cost of the sales expansion.